HZNP earnings call for the period ending September 30, 2019.
Horizon Pharma (HZNP) Q4 results: Revenues: $274.2M (-11.6%); Operating Loss: ($75.6M) (+41.9%); Net Loss: ($46.4M) (+64.4%); Loss Per Share: ($0.28) (+65.4%); Non-GAAP EPS:...
By Michael Erman NEW YORK (Reuters) - Drugmakers opened the new year by raising U.S. prices on dozens of medicines, but early data showed the increases generally remained within a...
Horizon Therapeutics plc (NASDAQ:HZNP) reported third-quarter 2019 adjusted earnings of 64 cents per share, which beat the Zacks Consensus Estimate of 51 cents but declined from...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Technical Indicators||Strong Buy||Strong Buy||Strong Buy||Strong Buy||Strong Buy|
|Summary||Strong Buy||Strong Buy||Strong Buy||Strong Buy||Strong Buy|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Doji Star Bearish||5H||Current|
|Three Outside Up||1D||Current|
|Bullish Engulfing||1D||1||Nov 15, 2019|
|Evening Star||1D||2||Nov 14, 2019|
|Deliberation Bearish||1D||3||Nov 13, 2019|
|First Majestic Silver||10.84||10.87||10.53||+0.24||+2.26%||2.82M||18:30:00|
Horizon Therapeutics plc, formerly Horizon Pharma plc, is a rare disease biopharmaceutical company. The Company is focused on researching, developing and commercializing medicines that address needs for people impacted by rare and rheumatic diseases. The Company markets approximately 10 medicines, of which 6 are for rare and rheumatic diseases. The Company's marketed medicines are ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), PENNSAID (diclofenac sodium topical solution) 2% weight per weight (w/w), or PENNSAID 2%, PROCYSBI (cysteamine bitartrate) delayed-release capsules, QUINSAIR (aerosolized form of levofloxacin), RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium).Read More
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
|Securities Investor Protection Corporation (United States)||$0||Start Trading|
|National Futures Association (United States), Financial Industry Regulatory Authority (United States), Securities Investor Protection Corporation (United States)||$500||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.